We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Cartesian Therapeutics, Inc. (RNAC - Free Report) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks.
Last month, the company reported robust financial results for the fourth quarter and full-year 2025, while also providing key pipeline goals and updates for 2026. This might have been driving the recent share price rally.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of -23.5%. Revenues are expected to be $0.43 million, down 61.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Cartesian Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RNAC going forward to see if this recent jump can turn into more strength down the road.
Cartesian Therapeutics, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Precision BioSciences (DTIL - Free Report) , another stock in the same industry, closed the last trading session 4.7% higher at $7.88. DTIL has returned 12.1% in the past month.
For Precision BioSciences, the consensus EPS estimate for the upcoming report has changed +40.2% over the past month to -$0.27. This represents a change of +87.8% from what the company reported a year ago. Precision BioSciences currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC - Free Report) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks.
Last month, the company reported robust financial results for the fourth quarter and full-year 2025, while also providing key pipeline goals and updates for 2026. This might have been driving the recent share price rally.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of -23.5%. Revenues are expected to be $0.43 million, down 61.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Cartesian Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RNAC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Cartesian Therapeutics, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Precision BioSciences (DTIL - Free Report) , another stock in the same industry, closed the last trading session 4.7% higher at $7.88. DTIL has returned 12.1% in the past month.
For Precision BioSciences, the consensus EPS estimate for the upcoming report has changed +40.2% over the past month to -$0.27. This represents a change of +87.8% from what the company reported a year ago. Precision BioSciences currently has a Zacks Rank of #3 (Hold).